|
|||
![]() |
|||
2011-01-19 14:00:00 CET 2011-01-19 14:00:54 CET REGULATED INFORMATION Biotie Therapies - Major shareholder announcementsNotification according to Chapter 2, Section 10 of the Finnish Securities Market ActBIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 19 January 2011 at 3 p.m. Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act Biotie Therapies Corp. ("Company") has gained knowledge of the notification regarding the following change in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act. Burrill Life Sciences Capital Fund, L.P. has notified Company that as a result of the transactions carried out on 3 January 2011, certain change in holdings of the Company's shares has taken place. As a result of these transactions, the aggregate holdings of Burrill Life Sciences Capital Fund, L.P. has decreased below 5 per cent of the total number of shares and votes of the Company. Also the holdings of the General Partner, Burrill & Company (Life Sciences GP), LLC of Burrill Life Sciences Capital Fund, L.P has decreased below 5 per cent of the total number of shares and votes of the Company. The change in holdings in accordance with Chapter 2, Section 9 of the Finnish Securities Markets Act of which the Company has gained knowledge of is described below: Name of the Shares prior to the Shares after the % of shares after shareholder transactions transactions the transactions Burrill Life 9,613,435 0 0 Sciences Capital Fund, L.P. Total 9,613,435 0 0 The registered number of shares in Biotie Therapies Corp. is 176,003,931. Of these shares 14,747,084 are held by the Company and the number of outstanding shares and voting rights attached to the shares amounts thus to 161,256,847. Turku, 19 January 2011 Timo Veromaa President and CEO For further information, please contact: Virve Nurmi, Biotie Therapies Corp. tel. +358 2 274 8900 e-mail:virve.nurmi@biotie.com DISTRIBUTION NASDAQ OMX Helsinki Ltd Main Media www.biotie.com [HUG#1480784] |
|||
|